Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173338 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
A Phase 1 study, sponsored by Augusta University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04173338 is a Phase 1 study that was terminated before completion, run by Augusta University. The registered enrollment target is 9 participants.
The verdict
NCT04173338, a Phase 1 study, was terminated before completion, sponsored by Augusta University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Interventions
- DRUG Pemetrexed
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04173338
The ClinicalTrials.gov registry entry for NCT04173338 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT04173338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04173338 about?
NCT04173338 is a clinical study titled "Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma". This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
What is the current status of trial NCT04173338?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-01-23. Estimated completion is 2022-03-28.
What interventions are being tested in trial NCT04173338?
The interventions under investigation include: Pemetrexed (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04173338?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.